Q2 2019 was a landmark quarter for Prometic with a recapitalisation comprising the conversion of $228.9m of debt and $114.4m in new equity issuance. Over H1 total cash has gone from $7.4m to $81m, off set by total debt of just $9.2m. The net loss of $133.7m resulted largely from the non cash element of the loss on extinguishment of a loan of $87.4m.
15 Aug 2019
Balance sheet transformed. Bioseparations performing well. Sharp focus on value driving clinical priorities
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Balance sheet transformed. Bioseparations performing well. Sharp focus on value driving clinical priorities
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
15 Aug 2019 -
Author:
Derren Nathan -
Pages:
6
Q2 2019 was a landmark quarter for Prometic with a recapitalisation comprising the conversion of $228.9m of debt and $114.4m in new equity issuance. Over H1 total cash has gone from $7.4m to $81m, off set by total debt of just $9.2m. The net loss of $133.7m resulted largely from the non cash element of the loss on extinguishment of a loan of $87.4m.